Cytokinetics (CYTK) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $72.72 --0%
Revenue Growth %: +1,960.6%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +1,960.6%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($0.51), in-line with the analyst estimate of ($0.51). Revenue for the quarter came in at $6.22 million versus the consensus estimate of $5.19 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
- Hyperion DeFi raises FY26 guidance, launches $20M buyback
- After an 18% summer selloff in chip stocks, Citi asks what comes next
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
